After surgery for an early lung cancer, most people hear the same question at every follow-up visit: has it come back? A study published this summer and widely reported on October 23, 2026, suggests that a blood test could one day help answer it much sooner than a scan can. The test looks for tiny fragments of tumor DNA in the blood. In a small group of people operated on for the earliest stage of lung adenocarcinoma, it spotted recurrence a median of 16.7 months before doctors could see it on a scan or in the clinic.
That is promising, but it is not yet a routine test. This article explains what the researchers did, what the numbers mean in plain language, what this changes for you today, and which questions to ask your care team.
What the new study actually tested
A team at NYU Langone Health followed 42 people who had surgery for stage IA non-small cell lung cancer, the earliest and smallest stage. For most of them surgery is curative, but some cancers do return. The researchers sequenced each patient’s tumor to learn its unique pattern of genetic changes, then looked for that same pattern in blood samples taken over time. The work was published in the Journal of Molecular Diagnostics.
Because the test is built around each person’s own tumor, it works like a fingerprint search: it asks whether DNA carrying that specific signature is circulating in the bloodstream. This approach is often called a liquid biopsy, because a blood draw replaces a tissue sample.
The key numbers, in plain language
Among the 12 patients whose cancer later came back, the blood test had flagged 9 of them in advance. That is a sensitivity of 75%. Among patients whose cancer did not return, the test correctly stayed negative in about 83% of cases, and a negative result was right about 89% of the time, according to the news report on the study. In patients with a positive blood test and a confirmed recurrence, the signal appeared a median of 16.7 months ahead of clinical or scan-based detection.
The test could also help in tricky situations: it helped tell a true recurrence apart from a second, unrelated new lung tumor in cases where pathology alone was hard to interpret.
| Domanda | What the study found | Cosa significa per te |
|---|---|---|
| How many people? | 42 people with stage IA disease | A small group, so results can shift in larger trials |
| Did it catch recurrences? | 9 of 12 (75%) | One in four recurrences was still missed |
| How reliable was a negative? | Right about 89% of the time | A negative result is reassuring, not a guarantee |
| How early? | Median 16.7 months before scans | Earlier warning, but benefit to survival is not yet proven |
What this does not prove yet
Finding a recurrence earlier is not the same as living longer. No study here shows that acting on a positive blood test changes outcomes, and the authors themselves call for larger prospective studies before routine use. The sample is small, it was analyzed retrospectively, and several authors work for the company that developed the sequencing method. None of that invalidates the findings, but it is a good reason to read them as an early signal rather than a new standard of care.
What earlier research says about ctDNA after lung surgery
This study fits into a larger body of work. A systematic review and meta-analysis published in late 2025 pooled 13 studies covering 1,309 people operated on for non-small cell lung cancer. Detecting ctDNA right after surgery was linked to a much higher risk of recurrence: the hazard ratio was 6.41, which roughly means that, at any given moment, people with a positive result were several times more likely to relapse than those with a negative one. Repeated testing over time showed the strongest link, with a hazard ratio of 8.70. Positive results after adjuvant chemotherapy were also associated with worse outcomes.
In everyday terms, ctDNA looks like a reliable marker of risk. What researchers still need to show is that using it to guide treatment helps people live longer or better.
What follow-up looks like today
For now, follow-up after lung cancer treatment relies on clinic visits, imaging such as CT scans, and sometimes lab work. The American Cancer Society notes that, for people with no remaining signs of cancer, many doctors suggest visits about every 3 months for the first couple of years, about every 6 months for several more years, and at least yearly after 5 years, though schedules differ. The National Cancer Institute reminds patients that non-small cell lung cancer can come back, and that follow-up tests exist precisely to look for that.
If you want the fundamentals, read our complete guide to lung cancer symptoms, diagnosis, and treatment. To see why blood tests are not yet a substitute for a scan in screening, see our explainer on lung cancer blood tests and CT screening.
Ultimi progressi scientifici
The science of tracking cancer through the blood is moving quickly. Two things are worth knowing. First, tests built around a person’s own tumor can pick up very small amounts of leftover cancer DNA, which is why they can sometimes raise a flag long before a scan does. Second, the same idea is being tested in other cancers: earlier we covered a ctDNA study of breast cancer recurrence, which showed a similar pattern of earlier warning but unanswered questions about benefit.
What this changes for you: if you are being followed after lung cancer surgery, you may hear about ctDNA testing from your oncologist or in a clinical trial. It is reasonable to ask about it, but it should add to your usual follow-up, never replace it.
Questions to ask your oncologist
- Is a ctDNA test available for my situation, and is it part of a trial or a standard service?
- What would we do differently if the result were positive, and what if it were negative?
- Would the test need my tumor sample, and how long would results take?
- Who pays for it, and will my regular scans and visits stay on schedule?
Quando è opportuno consultare il medico
Do not wait for a scheduled visit if you notice a new cough that does not go away, coughing up blood, unexplained weight loss, new shortness of breath, chest pain, or bone pain. These symptoms have many causes, but they deserve prompt attention after lung cancer. Quitting or staying away from tobacco remains one of the most useful steps for lowering the chance of another lung cancer.
Blood tests reported in your routine lab results, such as a CEA blood test and how to read the results, can sometimes be part of follow-up, but they are not a reliable stand-alone check for recurrence.
Glossario
- ctDNA (circulating tumor DNA): tiny fragments of DNA released by cancer cells into the blood.
- Biopsia liquida: a blood test that looks for traces of cancer instead of taking a tissue sample.
- Minimal residual disease: a very small amount of cancer that remains after treatment and is too small to see on scans.
- Sensibilità: how often a test is positive in people who truly have the condition.
- Stage IA: the earliest, smallest stage of non-small cell lung cancer.
- Hazard ratio: a measure of how much more likely an event, here recurrence, is in one group than in another.
FAQ
Can a blood test detect lung cancer coming back?
Research suggests that ctDNA blood tests can sometimes detect a recurrence before scans, but they are still being studied and are not standard follow-up.
How often does lung cancer come back after surgery?
It depends on the stage and type of cancer. Even in early stages, a recurrence can happen, which is why regular follow-up matters. Your oncologist can estimate the risk for your situation.
Un risultato negativo al ctDNA significa che sono guarita?
No. In the new study, about one in four recurrences was missed by the blood test, so a negative result should be read alongside scans and clinical exams.
Is a ctDNA test covered by insurance?
Coverage varies by plan and by the reason for testing. Ask your care team and insurer before sampling.
Should I ask for this test?
You can raise it with your oncologist, who can say whether it is appropriate for your tumor type and stage or whether a clinical trial exists.
Fonti
- Snuderl M, et al. Predicting Recurrence of Stage IA Lung Adenocarcinoma Using Circulating Tumor Cell-Free DNA Whole-Genome Mutational Signatures. Journal of Molecular Diagnostics, 2026 (retrieved from PubMed). DOI
- Khan AU, et al. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology, 2025 (retrieved from PubMed). DOI
- Medical News Today: Blood test may detect lung cancer recurrence months before scans
- National Cancer Institute: Non-Small Cell Lung Cancer Treatment (PDQ), Patient Version
- American Cancer Society: Living as a Lung Cancer Survivor
- MedlinePlus: Lung Cancer
Altri articoli
- Esame del sangue per la recidiva del tumore al seno: cosa mostra il nuovo studio sul ctDNA
- Lung cancer blood test and CT screening
- CEA (antigene carcinoembrionario): valori normali e alti
Scopri cosa dicono i tuoi esami del sangue con AI DiagMe
Follow-up often means a stack of lab reports and unfamiliar numbers. Scopri i tuoi referti con AI DiagMe, a plain-language interpretation reviewed by a committee of physicians.
